Roluperidone Relapse Prevention Without Dopamine Interference
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for schizophrenia, particularly those targeting negative symptoms, often interfere with dopamine neurotransmission, leading to secondary negative symptoms like Parkinsonism and sedation, and there are no approved treatments for preventing relapse in schizophrenia patients in the United States.
Innovation Solution
Roluperidone, a novel cyclic amido derivative with selective receptor antagonism, is administered to schizophrenia patients with stable positive or negative symptoms to prevent relapse, avoiding interference with dopamine-driven reward systems and secondary negative symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antipsychotic treatments are used to treat schizophrenia, then positive symptoms are controlled, but secondary negative symptoms like Parkinsonism and sedation occur due to dopamine interference
Solution Approach 1:
The patent changes the receptor affinity parameters of the treatment agent by selecting Roluperidone, which has very low or no affinity for dopaminergic receptors while maintaining antagonistic activities for serotoninergic 5-HT2A, sigma2, and α1A-adrenergic receptors. This parameter change in receptor selectivity allows treatment of positive symptoms without blocking dopamine-driven reward systems, thereby preventing secondary negative symptoms like Parkinsonism and sedation
2Reliability
If Roluperidone is administered to prevent relapse, then relapse risk is reduced and symptom stability is maintained, but the treatment must avoid interfering with dopamine neurotransmission
Solution Approach 1:
The patent applies local quality by targeting specific receptor subtypes (5-HT2A, sigma2, α1A-adrenergic) with high selectivity while deliberately avoiding dopaminergic receptors. This localized receptor specificity allows the drug to exert therapeutic effects on positive symptoms and prevent relapse without affecting dopamine neurotransmission in reward pathways, thus avoiding harmful interference with the dopamine system
Data Source
Figure 1
Figure 2
Figure 3
AI summary
This application pertains to methods of preventing relapse in schizophrenia patients that include administering a therapeutically effective amount of Roluperidone to the schizophrenia patient.